glp-1 weight loss drug market news today Investing in Drugs: Eli Lilly, Novo Nordisk, and Viking Therapeutics in 2026 - and Statistics FuturHealth | Our obesity specialist,

Description

Liang L, Chen J, Zhan L, et al

Although prospective studies specifically targeting PCOS + MASLD with pregnancy outcomes as the primary endpoint are currently lacking, a robust inference can be drawn based on the pathophysiological framework of MASLD and evidence from the general population: proactively identifying and reducing MASLD and ectopic fat load prior to pregnancy may be a key step in improving both periconception outcomes and long-term prognosis (68, 76)

Mazdutide , a dual GLP-1/glucagon agonist, is in development and shows promising results in early trials, particularly in Asian populations

When it comes to going off GLP-1s, not much guidance is available When Kessler reached his personal weight-loss target, he was developing some slight abdominal pains, so he decided to stop